HomeCompareLABP vs BTI

LABP vs BTI: Dividend Comparison 2026

LABP yields 8.72% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $2.1K in total portfolio value· pulled ahead in Year 9
10 years
LABP
LABP
● Live price
8.72%
Share price
$22.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.6K
Annual income
$1,512.64
Full LABP calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — LABP vs BTI

📍 BTI pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLABPBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LABP + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LABP pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LABP
Annual income on $10K today (after 15% tax)
$741.39/yr
After 10yr DRIP, annual income (after tax)
$1,285.74/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, BTI beats the other by $1,082.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LABP + BTI for your $10,000?

LABP: 50%BTI: 50%
100% BTI50/50100% LABP
Portfolio after 10yr
$36.7K
Annual income
$2,149.64/yr
Blended yield
5.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

LABP
No analyst data
Altman Z
-3.1
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LABP buys
0
BTI buys
0
No recent congressional trades found for LABP or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLABPBTI
Forward yield8.72%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$35.6K$37.7K
Annual income after 10y$1,512.64$2,786.64
Total dividends collected$11.9K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: LABP vs BTI ($10,000, DRIP)

YearLABP PortfolioLABP Income/yrBTI PortfolioBTI Income/yrGap
1$11,572$872.22$11,299$598.92+$273.00LABP
2$13,326$943.32$12,794$703.91+$532.00LABP
3$15,274$1,015.18$14,518$829.07+$756.00LABP
4$17,430$1,087.46$16,513$978.64+$917.00LABP
5$19,810$1,159.83$18,827$1,157.84+$983.00LABP
6$22,429$1,231.95$21,518$1,373.12+$911.00LABP
7$25,302$1,303.55$24,657$1,632.46+$645.00LABP
8$28,448$1,374.36$28,329$1,945.74+$119.00LABP
9← crossover$31,883$1,444.13$32,637$2,325.33$754.00BTI
10$35,628$1,512.64$37,708$2,786.64$2.1KBTI

LABP vs BTI: Complete Analysis 2026

LABPStock

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Full LABP Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this LABP vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LABP vs SCHDLABP vs JEPILABP vs OLABP vs KOLABP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.